Literature DB >> 31624757

Hair regrowth following fecal microbiota transplantation in an elderly patient with alopecia areata: A case report and review of the literature.

Wen-Rui Xie1, Xiao-Ya Yang2, Harry Hua-Xiang Xia1, Li-Hao Wu1, Xing-Xiang He3.   

Abstract

BACKGROUND: Alopecia areata is a hair loss disease associated with genetics, autoimmunity, and other factors. There is an intriguing link between alopecia areata and gut dysbiosis. Fecal microbiota transplantation (FMT) has been recommended to treat Clostridium difficile (previously known as Clostridioides difficile) infection, and has also shown potentials in the treatment of inflammatory bowel disease, irritable bowel syndrome, and non-alcohol fatty liver disease. CASE
SUMMARY: An 86-year-old man, with a history of sigmoid colon carcinoma, suffered from recurrent abdominal pain and distension, and diarrhea for six months, with inappetence. At admission, he was also diagnosed with depression. Upon physical examination, the patient presented with a 1.5 cm × 2.0 cm alopecia areata on his right occiput. Due to the negative results of laboratory testing, capsule endoscopy, and colonoscopy, the patient was diagnosed with noninfectious diarrhea, depressive disorder, and patchy alopecia areata. Considering that noninfectious diarrhea in the elderly patient was mainly caused by gut dysbiosis, he was given six rounds of FMT. His diarrhea improved remarkably one month after FMT, with improved appetite and disappearance of abdominal pain, distension, and depressive symptoms. Surprisingly, he reported new hair growth on the affected region of his scalp, with some of his white hair gradually turning to black, without taking any other therapies for alopecia areata before and after FMT.
CONCLUSION: FMT might act as a potential therapy for patients who suffer from alopecia areata. Large and well-designed studies are required to confirm the role of FMT in alopecia areata. ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Alopecia areata; Autoimmune disease; Case report; Fecal microbiota transplantation; Gut microbiota; Psychopathogenesis

Year:  2019        PMID: 31624757      PMCID: PMC6795734          DOI: 10.12998/wjcc.v7.i19.3074

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


Core tip: Fecal microbiota transplantation (FMT) has been recommended to treat Clostridium difficile (previously known as Clostridioides difficile) infection, and has shown its potential role in the treatment of inflammatory bowel disease, irritable bowel syndrome, liver disease, and other disorders. This case report describes an elderly Chinese patient with alopecia areata who experienced restored hair growth and pigmentation after receiving FMT for his noninfectious diarrhea. Concurrently, the senile plaques on his face disappeared and his depressive symptoms improved.

INTRODUCTION

Alopecia areata involves a chronic inflammation that impacts on hair follicles and results in hair loss, and its etiology is associated with genetics, autoimmunity, and environmental factors[1]. Recent studies show that there is a close link between alopecia areata and gut dysbiosis[2,3]. In recent years, fecal microbiota transplantation (FMT), a strategy to treat gut dysbiosis through restoring a healthy gut microbiome, has been strongly recommended to treat Clostridium difficile (previously known as Clostridioides difficile) infection (CDI) in clinical practice[4], and it has also been employed to treat patients with other gut dysbiosis-related diseases, such as inflammatory bowel disease (IBD, including ulcerative colitis and Crohn’s disease), irritable bowel syndrome (IBS), liver disease, and constipation[5-9]. Here we present a case of alopecia areata in whom hair regrew following FMT.

CASE PRESENTATION

Chief complaints

On April 5, 2017, an 86-year-old man, suffering from recurrent abdominal pain and distension, and diarrhea, was seen at the Outpatient Department of Gastroenterology, the First Affiliated Hospital of Guangdong Pharmaceutical University.

History of present illness

The patient’s symptoms had sustained for six months, with inappetence. His stool frequency was 4–5 times per day, without fever or bloody purulent stool. At admission, he was also diagnosed with depression and treated with Deanxit (flupentixol and melitracen) tablets.

History of past illness

The patient had a history of sigmoid colon carcinoma and underwent surgical operation and sigmoidostomy for sigmoid colon carcinoma 6 years ago.

Personal and family history

The patient had a free personal and family history.

Physical examination upon admission

At admission, the patient’s temperature was 36.6 °C, heart rate was 78 bpm, respiratory rate was 20 breaths per minute, blood pressure was 123/72 mmHg, and body mass index (BMI) was 17.2 kg/m2. Upon physical examination, the patient presented with a 1.5 cm × 2.0 cm alopecia areata on his right occiput (no photo was taken). The abdomen was soft with no tenderness or rebound tenderness.

Laboratory examinations

Serum albumin was decreased at 35 g/L (normal range 40–55 g/L). Blood routine examination, stool routine examination, and fecal occult blood test were all negative.

Imaging examinations

The normal mucosae of the stomach and small intestine were observed on capsule endoscopy. Colonoscopy was conducted, which showed that the mucosa of the colon appeared to be normal (Figure 1).
Figure 1

Colonoscopy showing a normal colonic mucosa.

Colonoscopy showing a normal colonic mucosa.

FINAL DIAGNOSIS

According to the above examinations, we excluded infectious diarrhea on the basis of the negative results of laboratory testing, capsule endoscopy, and colonoscopy. The patient was diagnosed with noninfectious diarrhea, depressive disorder, and patchy alopecia areata.

TREATMENT

Due to the negative results of laboratory testing, capsule endoscopy, and colonoscopy, and no usage of antibiotic, we considered that noninfectious diarrhea in the elderly patient was mainly caused by gut dysbiosis[10-12], but not by diseases (including pancreatic exocrine insufficiency, bile acid malabsorption, gastrointestinal tumor, and Crohn’s disease) and antibiotic-associated colitis. Thus, the patient was given six rounds of FMT for noninfectious diarrhea on April 10, April 12, April 14, May 17, May 19, and May 22, 2017, respectively. The stool for FMT was obtained from a 22-year-old healthy male donor, in whom we conducted the routine screening for potential pathogens according to the selection criteria formulated by Zhang’s group[13,14]. The fresh fecal microbiota suspension, prepared with the automatic purification system (GenFMTer; FMT Medical, Nanjing, China), was administered through the lower digestive tract with a colonoscope, following the laboratory protocol formulated by Zhang’s group[13].

OUTCOME AND FOLLOW-UP

During the 18-mo follow-up after six rounds of FMT, with the last follow-up visit on November 22, 2018, his stool frequency was reduced to 1-2 times per day, with the improved appetite and no abdominal pain or distension. Specifically, his diarrhea improved remarkably one month after FMT. His depressive symptoms were also improved; his score on the Hamilton Depression Scale (HAM-D17)[15] was reduced from 30 points at administration to 13 points at the last visit. His BMI rose to 18.3 kg/m2, and serum albumin increased slightly to 38 g/L. Surprisingly, at the follow-up 4 wk after FMT, he reported new hair growth on the affected region of his scalp, with some of his white hair gradually turning to black, without taking any other therapies for alopecia areata before and after FMT. His hair growth maintained at the last visit (Figure 2). In addition, the senile plaques on his face disappeared at the same time (no photo was taken).
Figure 2

Hair regrowth on an elderly Chinese patient’s scalp after fecal microbiota transplantation. The patient’s scalp 1 mo (A), 4 mo (B), and 18 mo (C) after fecal microbiota transplantation, respectively.

Hair regrowth on an elderly Chinese patient’s scalp after fecal microbiota transplantation. The patient’s scalp 1 mo (A), 4 mo (B), and 18 mo (C) after fecal microbiota transplantation, respectively.

DISCUSSION

We present the case of an elderly Chinese patient who experienced new hair growth on the alopecia areata-affected regions of his scalp, with restoration of hair pigmentation, after receiving FMT, which was indicated for noninfectious diarrhea. Furthermore, his diarrhea and depressive symptoms improved and the senile plaques on his face disappeared at the same time. We speculate that all of these changes are related to altered gut microbiota after FMT. Gut dysbiosis plays a critical role in infectious diarrhea[16,17]. FMT has been performed to treat Clostridium difficile-associated diarrhea, which was more effective than vancomycin or placebo treatment[18]. Beyond infectious diarrhea, gut dysbiosis also plays an important role in noninfectious diarrhea[10-12]. A double-blind, random-ized, placebo-controlled, parallel-group, single-center trial revealed that symptoms of IBS, including diarrhea, got improved significantly after receiving FMT[7]. In our FMT trial center at the First Affiliated Hospital of Guangdong Pharmaceutical University, we have treated about 40 patients with diarrhea using FMT, showing significant symptom improvement (data not published). In this case, we conducted FMT in the elderly patient for his noninfectious diarrhea. During the treatment, we observed hair regrowth on the alopecia areata-affected regions of his scalp surprisingly. Clinical patterns of alopecia areata comprise patchy alopecia areata, alopecia totalis, and alopecia universalis[19]. The following factors contribute to the pathogenesis of alopecia areata: (1) Genetics: 62 genes have been identified to be involved in the pathogenesis of alopecia areata[19]; (2) Immune response: The loss of the immune privilege with the subsequent attack of autoreactive infiltrates on the hair follicle is considered to be the predominant cause of alopecia areata[1,19,20]; and (3) Other factors: Oxidative stress and infectious agents could lead to breakdown of the immune privilege and initiation of alopecia areata[19,20]. In addition, psychological stress may act as an aggravating factor in initiation and progression of alopecia areata, although this is controversial[20-23]. Several treatments do result in hair growth in patients with alopecia areata. First, application of local corticosteroids shows a positive curative effect in patchy alopecia areata. But this treatment cannot inhibit the development of alopecia areata at other sites[1,19]. Second, patients with extensive and rapidly progressive alopecia areata got benefits from application of systemic corticosteroids[19,24,25]. However, continued application is required to maintain hair growth in most cases[19]. Third, contact immunotherapy is effective for patients with patchy alopecia areata, not for those with alopecia totalis and alopecia universalis[19]. But a high relapse rate (62%) of this management becomes a disturbing issue[19]. Therefore, none of the treatments mentioned above has been ratified by the US FDA, indicating that a new and more effective therapeutic intervention aiming at new targets is needed. Recently, several studies demonstrated that gut dysbiosis plays critical roles in the onset of skin diseases, including atopic dermatitis and psoriasis[26-29]. However, the association between alopecia areata and gut dysbiosis awaits to be elucidated. Alopecia areata may link with other autoimmune diseases, especially with IBD[30]. A series of clinical cases reported that hair loss was found in patients with IBD[31-34], with little knowledge of its causes. Since gut dysbiosis is one of the major pathogenesis of IBD[35-37], gut dysbiosis may act as a common pathway coexisting with alopecia areata and IBD. Biotin (vitamin B7), a water-soluble vitamin, has the heavy reliance on bacterial production in guts. Hair loss is one of the symptoms of biotin deficiency[38], which is induced by a variety of factors, including IBD[39]. Lately recently, Hayashi et al[2] reported that alopecia was developed in biotin-deficient germ-free mice, with overgrowth of Lactobacillus murinus. The alopecia mice showed hair regrowth after supplementation of biotin, with reduction of Lactobacillus murinus, indicating that alopecia was caused mainly by gut dysbiosis, particularly overgrowth of Lactobacillus murinus, which consequently led to biotin deficiency[2]. Thus, it is not implausible that there exists a close link between gut dysbiosis and alopecia areata. Short-chain fatty acids (SCFAs), produced by gut microbiota, contribute to maintaining immunological homeostasis[40], via modulating the numbers and function of regulatory T cells (Tregs), which play critical role in the induction of alopecia areata[3,30]. Borde et al[3] hypothesized that propionate, one of SCFAs, would induce more tolerogenic Tregs through stimulating G protein-coupled receptors to protect the hair follicles against the immunological attack. They observed that hair regrowth in five out of five C3H/He J mice (a kind of mouse developing alopecia areata spontaneously) after 11 wk of propionate treatment, with an increased Treg/CD4+ ratio. Unfortunately, they failed to reproduce the positive results of hair regrowth when they repeated the study. Due to the vast varieties of gut microbiota, it is insufficient to restore the normal gut microbiota merely through supplying one of SCFAs, which leads to the inconclusive results. Nevertheless, the intriguing link between gut dysbiosis and alopecia areata does exist, and restoring a healthy gut, instead of supplying one to several kinds of SCFAs, will perform more effectively in treating alopecia areata. Vitamin D, one of the micronutrients in our daily diet, is well-known for the effect of maintaining the normal levels of calcium and phosphorus in the blood[41]. Vitamin D exerts its biological functions through conversion into its active form of 1,25(OH)2D3 by the activating enzyme Cyp27B1[42]. 1,25(OH)2D3 binds to vitamin D receptor (VDR) to possess biological activities[43]. Growing evidence demonstrates that 1,25 (OH)2D3 deficiency is associated with alopecia areata[44-46], in which VDR deficiency plays a vital role[47-49]. On one hand, a recent study indicated that 1,25(OH)2D3 deficiency induced gut dysbiosis, leading to a reduction in SCFAs production[50]. On the other hand, several studies have shown that the expression of VDR and Cyp27B1 is regulated by gut microbiota[51-53]. Thus, it is unclear which takes the main responsi-bility for the onset of alopecia areata, although it is likely that there exists a bidirectional relationship between 1,25(OH)2D3 and gut microbiota and between 1,25(OH)2D3 deficiency and gut dysbiosis [43]. FMT is considered a safe and effective method to restore a healthy gut microbial environment, and displays astonishing clinical efficacy for recurrent CDI, IBD, IBS, liver disease, and other disorders[54-57]. The rationale for FMT restoring health is still unclear. Ooijevaar et al[58] proposed that there could be two pathways, the direct and indirect pathways. In the direct pathway, some beneficial bacteria and nutrients are transferred directly with FMT to compete with the pathogenic bacteria and replenish the missing nutrients, the process of which is unrelated to the host. In the indirect pathway, host-related factors, including immunomodulation and mechanical barrier function, are involved. This widespread efficacy of FMT provides a clue that FMT might also serve as a potential therapy for alopecia areata via the restoration of gut microbiota balance[3,30]. In 2017, Rebello et al[59] reported that two patients with alopecia universalis experienced hair regrowth after FMT used for recurrent CDI. Consistent with these two cases, the elderly patient with patchy alopecia areata in this case demonstrated long-term hair growth after FMT for noninfectious diarrhea (Table 1). These observations suggest that FMT contributes to hair regrowth by replenishing the gut microbiota. Restoration of a healthy gut microbial environment might lead to improvement of the absorption and synthesis of nutrients, including amino acid/proteins, biotin, SCFAs, and vitamin D, by immunomodulation, which ultimately results in hair regrowth. In this case, the elderly patient got his nutritional status improved after FMT, as his BMI and serum albumin increased slightly. Unfortunately, we could not provide the levels of biotin and vitamin D of this patient before and after FMT; acquisition of this information might help to elucidate the mechanism by which FMT results in hair regrowth.
Table 1

Case reports of hair regrowth in patients with alopecia after fecal microbiota transplantation

ReferenceAgeSexDiseasePattern of alopeciaPrevious therapies for alopeciaOther therapies for alopecia during FMTHair regrowth after FMT
Rebello et al[59], 201738MaleCDIAlopecia universalisSteroid injectionNo8 wk
Rebello et al[59], 201720MaleCDIAlopecia universalisIntralesional corticosteroid injections2 additional intralesional corticosteroid injections after FMTA few months
86MaleNoninfectious diarrheaAlopecia areataNoNo4 wk

CDI: Clostridioides difficile (formerly Clostridium difficile) infection; FMT: Fecal microbiota transplantation.

Case reports of hair regrowth in patients with alopecia after fecal microbiota transplantation CDI: Clostridioides difficile (formerly Clostridium difficile) infection; FMT: Fecal microbiota transplantation. In addition to hair regrowth, the elderly patient we report here reported that his hair color returned and the senile plaques on his face disappeared. The pathogenesis of canities has not been completely understood yet. Certain organ-specific autoimmune disorders may contribute to the process of canities[60], which gives us a hint that the gut microbiota may be associated with the process of canities. Hence, our elderly patient could get his hair color returned after restoration of the balance of the gut microbial environment. As the gut microbiota acts as a direct mediator of psychopathology through the gut–brain axis[61,62], the patient’s depressive symptoms were also improved after FMT.

CONCLUSION

In conclusion, despite the astonishing therapeutic effect described in this report, as well as in the report by Rebello et al[59], further investigations on the role of the gut microbiota in alopecia areata through large and well-designed clinical trials are required to support the clinical application of FMT as a treatment option for this distressing disease.
  61 in total

1.  Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes.

Authors:  P Bech; M Kastrup; O J Rafaelsen
Journal:  Acta Psychiatr Scand Suppl       Date:  1986

2.  Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis.

Authors:  Han Song; Young Yoo; Junghyun Hwang; Yun-Cheol Na; Heenam Stanley Kim
Journal:  J Allergy Clin Immunol       Date:  2015-10-01       Impact factor: 10.793

Review 3.  Mechanisms of tolerance and potential therapeutic interventions in Alopecia Areata.

Authors:  Gabriel Skogberg; Sonya Jackson; Annika Åstrand
Journal:  Pharmacol Ther       Date:  2017-05-22       Impact factor: 12.310

4.  Lack of the vitamin D receptor is associated with reduced epidermal differentiation and hair follicle growth.

Authors:  Zhongjion Xie; László Komuves; Qian-Chun Yu; Hashem Elalieh; Dean C Ng; Colin Leary; Sandra Chang; Debra Crumrine; Tatsuya Yoshizawa; Shigeaki Kato; Daniel D Bikle
Journal:  J Invest Dermatol       Date:  2002-01       Impact factor: 8.551

Review 5.  The role of the intestinal microbiota in the development of atopic disorders.

Authors:  J Penders; E E Stobberingh; P A van den Brandt; C Thijs
Journal:  Allergy       Date:  2007-08-17       Impact factor: 13.146

6.  Pulse corticosteroid therapy for alopecia areata: study of 139 patients.

Authors:  Takeshi Nakajima; Shigeki Inui; Satoshi Itami
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

Review 7.  Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead.

Authors:  Thomas Borody; Monika Fischer; Scott Mitchell; Jordana Campbell
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

Review 8.  Increased prevalence of vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis.

Authors:  S Lee; B J Kim; C H Lee; W S Lee
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-05-18       Impact factor: 6.166

9.  European consensus conference on faecal microbiota transplantation in clinical practice.

Authors:  Giovanni Cammarota; Gianluca Ianiro; Herbert Tilg; Mirjana Rajilić-Stojanović; Patrizia Kump; Reetta Satokari; Harry Sokol; Perttu Arkkila; Cristina Pintus; Ailsa Hart; Jonathan Segal; Marina Aloi; Luca Masucci; Antonio Molinaro; Franco Scaldaferri; Giovanni Gasbarrini; Antonio Lopez-Sanroman; Alexander Link; Pieter de Groot; Willem M de Vos; Christoph Högenauer; Peter Malfertheiner; Eero Mattila; Tomica Milosavljević; Max Nieuwdorp; Maurizio Sanguinetti; Magnus Simren; Antonio Gasbarrini
Journal:  Gut       Date:  2017-01-13       Impact factor: 23.059

Review 10.  Fecal microbiota transplantation in cancer management: Current status and perspectives.

Authors:  Danfeng Chen; Jingyi Wu; Duochen Jin; Bangmao Wang; Hailong Cao
Journal:  Int J Cancer       Date:  2018-12-30       Impact factor: 7.396

View more
  14 in total

1.  Impact of cap-assisted colonoscopy during transendoscopic enteral tubing: A randomized controlled trial.

Authors:  Quan Wen; Kang-Jian Liu; Bo-Ta Cui; Pan Li; Xia Wu; Min Zhong; Lu Wei; Hua Tu; Yu Yuan; Da Lin; Wen-Hung Hsu; Deng-Chyang Wu; Hong Yin; Fa-Ming Zhang
Journal:  World J Gastroenterol       Date:  2020-10-21       Impact factor: 5.742

Review 2.  A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.

Authors:  Shokufeh Ghasemian Sorboni; Hanieh Shakeri Moghaddam; Reza Jafarzadeh-Esfehani; Saman Soleimanpour
Journal:  Clin Microbiol Rev       Date:  2022-01-05       Impact factor: 26.132

Review 3.  Myron Gordon Award paper: Microbes, T-cell diversity and pigmentation.

Authors:  I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2021-01-27       Impact factor: 4.159

Review 4.  The gut microbiome as a modulator of healthy ageing.

Authors:  Tarini Shankar Ghosh; Fergus Shanahan; Paul W O'Toole
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-04-25       Impact factor: 73.082

5.  Colonic Transendoscopic Enteral Tubing: Route for a Novel, Safe, and Convenient Delivery of Washed Microbiota Transplantation in Children.

Authors:  Min Zhong; Heena Buch; Quan Wen; Chuyan Long; Bota Cui; Faming Zhang
Journal:  Gastroenterol Res Pract       Date:  2021-01-15       Impact factor: 2.260

Review 6.  The Human Skin Microbiome in Selected Cutaneous Diseases.

Authors:  Silvia Carmona-Cruz; Luz Orozco-Covarrubias; Marimar Sáez-de-Ocariz
Journal:  Front Cell Infect Microbiol       Date:  2022-03-07       Impact factor: 5.293

7.  Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review.

Authors:  Arthi Chinna Meyyappan; Evan Forth; Caroline J K Wallace; Roumen Milev
Journal:  BMC Psychiatry       Date:  2020-06-15       Impact factor: 3.630

8.  Colonic transendoscopic tube-delivered enteral therapy (with video): a prospective study.

Authors:  Ting Zhang; Chuyan Long; Bota Cui; Heena Buch; Quan Wen; Qianqian Li; Xiao Ding; Guozhong Ji; Faming Zhang
Journal:  BMC Gastroenterol       Date:  2020-05-06       Impact factor: 3.067

9.  Awareness and attitude of fecal microbiota transplantation through transendoscopic enteral tubing among inflammatory bowel disease patients.

Authors:  Min Zhong; Yang Sun; Hong-Gang Wang; Cicilia Marcella; Bo-Ta Cui; Ying-Lei Miao; Fa-Ming Zhang
Journal:  World J Clin Cases       Date:  2020-09-06       Impact factor: 1.337

Review 10.  Getting Under the Skin: Targeting Cutaneous Autoimmune Disease.

Authors:  Matthew D Vesely
Journal:  Yale J Biol Med       Date:  2020-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.